Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy.

ABSTRACT:

Background

EPIC1 is an oncogenic long non-coding ribonucleic acid (RNA) that promotes cell growth and cell-cycle progression and inhibits apoptosis in several cancer cell lines. However, clinical studies on EPIC1 in breast cancer, specifically in the neoadjuvant setting, are relatively few.

Methods

Patients treated with weekly paclitaxel-cisplatin-based neoadjuvant chemotherapy after core-needle biopsy were included in the study. Real-time quantitative polymerase chain reaction assays were performed to detect EPIC1 expression.

Results

Among all patients included in this study (n = 111), higher EPIC1 expression was associated with estrogen receptor negativity, human epidermal growth factor receptor 2 positivity, higher Ki67 index, and higher histologic grade. Mu

SUBMITTER: Xu Y 

PROVIDER: S-EPMC7383657 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature